Environment-mediated drug resistance: A major contributor to minimal residual disease

Nature Reviews Cancer

Volumn 9, Issue 9, 2009, Pages 665-674

  Meads, Mark B ^a   Gatenby, Robert A ^a   Dalton, William S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; ANTHRACYCLINE; BCL2 RELATED PROTEIN A1; BORTEZOMIB; CHEMOKINE RECEPTOR CXCR4; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYTARABINE; FAS ANTIGEN; FIBROBLAST GROWTH FACTOR; FLICE INHIBITORY PROTEIN; INTERLEUKIN 6; MELPHALAN; N [1,4,8,11 TETRAAZACYCLOTETRADECANYL 1,4 PHENYLENEBIS(METHYLENE)] 2 (AMINOMETHYL)PYRIDINE; PHOSPHOTRANSFERASE INHIBITOR; PREDNISONE; S PHASE KINASE ASSOCIATED PROTEIN 2; SIMVASTATIN; STAT3 PROTEIN; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CELL ADHESION; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LUNG SMALL CELL CANCER; LYMPHOBLASTOMA; MICROENVIRONMENT; MINIMAL RESIDUAL DISEASE; MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STROMA CELL; TUMOR CELL;

DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASM, RESIDUAL; NEOPLASMS; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 69249087671     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2714     Document Type: Review

References (108)

1. Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A. & Dalton, W. S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93, 1658-1667 (1999).
2. Meads, M. B., Hazlehurst, L. A. & Dalton, W. S. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin. Cancer Res. 14, 2519-2526 (2008).
3. Cordes, N., Seidler, J., Durzok, R., Geinitz, H. & Brakebusch, C. β1-integrin-mediated signaling essentially contributes to cell survival after radiationinduced genotoxic injury. Oncogene 25, 1378-1390 (2006).
4. Hazlehurst, L. A., Argilagos, R. F. & Dalton, W. S. β1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells. Br. J. Haematol. 136, 269-275 (2007).
5. Shain, K. H., Landowski, T. H. & Dalton, W. S. Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J. Immunol. 168, 2544-2553 (2002).
6. Skp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. Blood 110, 1631-1638 (2007).
7. Bidard, F. C. et al. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin. Cancer Res. 14, 3306-3311 (2008).
8. Braun, S. et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 353, 793-802 (2005).
9. Braun, S. et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J. Clin. Oncol. 18, 80-86 (2000).
10. Wiedswang, G. et al. Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clin. Cancer Res. 10, 5342-5348 (2004).
11. Matsunaga, T. et al. Interaction between leukemiccell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nature Med. 9, 1158-1165 (2003).
12. Bellamy, W. T., Dalton, W. S., Gleason, M. C., Grogan, T. M. & Trent, J. M. Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res. 51, 995-1002 (1991).
13. Hazlehurst, L. A. et al. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res. 63, 7900-7906 (2003).
14. Teicher, B. A. et al. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 247, 1457-1461 (1990).
15. Goldie, J. H. & Coldman, A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 63, 1727-1733 (1979).
16. Feller, N. et al. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 18, 1380-1390 (2004).
17. Hess, C. J. et al. Gene expression profiling of minimal residual disease in acute myeloid leukaemia by novel multiplex-PCR-based method. Leukemia 18, 1981-1988 (2004).
18. Brisco, J. et al. Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. Blood 87, 5251-5256 (1996).
19. Heiss, M. M. et al. Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow. J. Clin. Oncol. 20, 2005-2016 (2002).
20. Campana, D. Status of minimal residual disease testing in childhood haematological malignancies. Br. J. Haematol. 143, 481-489 (2008).
21. Pui, C. H. & Evans, W. E. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 354, 166-178 (2006).
22. Matsunaga, T. et al. Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia. Leukemia 22, 353-360 (2008).
23. Becker, P. S. et al. Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. Blood 113, 866-874 (2009).
24. de la Fuente, M. T. et al. Involvement of p53 in α4β1 integrin-mediated resistance of B-CLL cells to fludarabine. Biochem. Biophys. Res. Commun. 311, 708-712 (2003).
25. Folgiero, V. et al. Induction of ErbB-3 expression by α6β4 integrin contributes to tamoxifen resistance in ERβ1-negative breast carcinomas. PLoS ONE 3, e1592 (2008).
26. Yao, E. S. et al. Increased β1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res. 67, 659-664 (2007).
27. Oshita, F. et al. Increased expression of integrin β1 is a poor prognostic factor in small-cell lung cancer. Anticancer Res. 22, 1065-1070 (2002).
28. Graf, M. et al. Expression of MAC-1 (CD11b) in acute myeloid leukemia (AML) is associated with an unfavorable prognosis. Am. J. Hematol. 81, 227-235 (2006).
29. Vuoristo, M. et al. Increased gene expression levels of collagen receptor integrins are associated with decreased survival parameters in patients with advanced melanoma. Melanoma Res. 17, 215-223 (2007).
30. Nikkola, J. et al. Integrin chains β1 and αv as prognostic factors in human metastatic melanoma. Melanoma Res. 14, 29-37 (2004).
31. Sethi, T. et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nature Med. 5, 662-668 (1999).
32. Sherman-Baust, C. A. et al. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 3, 377-386 (2003).
33. Recher, C. et al. Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. Cancer Res. 64, 3191-3197 (2004).
34. Cario, G. et al. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. Blood 105, 821-826 (2005).
35. Flotho, C. et al. Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. Blood 108, 1050-1057 (2006).
36. van Stijn, A. et al. Minimal residual disease in acute myeloid leukemia is predicted by an apoptosisresistant protein profile at diagnosis. Clin. Cancer Res. 11, 2540-2546 (2005).
37. Flotho, C. et al. A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. Blood 110, 1271-1277 (2007).
38. Tlsty, T. D. & Coussens, L. M. Tumor stroma and regulation of cancer development. Annu. Rev. Pathol. 1, 119-150 (2006).
39. Finak, G. et al. Stromal gene expression predicts clinical outcome in breast cancer. Nature Med. 14, 518-527 (2008).
40. Hawsawi, N. M. et al. Breast carcinoma-associated fibroblasts and their counterparts display neoplasticspecific changes. Cancer Res. 68, 2717-2725 (2008).
41. Ohuchida, K. et al. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res. 64, 3215-3222 (2004).
42. Polyak, K., Haviv, I. & Campbell, I. G. Co-evolution of tumor cells and their microenvironment. Trends Genet. 25, 30-38 (2009).
43. Lenz, G. et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med. 359, 2313-2323 (2008).
44. Fridman, R. et al. Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc. Natl Acad. Sci. USA 87, 6698-6702 (1990).
45. Mori, Y. et al. Anti-α4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 104, 2149-2154 (2004).
46. Park, C. C. et al. β1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res. 66, 1526-1535 (2006).
47. Park, C. C., Zhang, H. J., Yao, E. S., Park, C. J. & Bissell, M. J. β1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res. 68, 4398-4405 (2008).
48. Hazlehurst, L. A., Damiano, J. S., Buyuksal, I., Pledger, W. J. & Dalton, W. S. Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 19, 4319-4327 (2000).
49. Fu, Y. et al. Overexpression of integrin β1 inhibits proliferation of hepatocellular carcinoma cell SMMC-7721 through preventing Skp2- dependent degradation of p27 via PI3K pathway. J. Cell Biochem. 102, 704-718 (2007).
50. Hartmann, T. N., Burger, J. A., Glodek, A., Fujii, N. & Burger, M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 24, 4462-4471 (2005).
51. Hodkinson, P. S. et al. ECM overrides DNA damageinduced cell cycle arrest and apoptosis in small-cell lung cancer cells through β1 integrin-dependent activation of PI3-kinase. Cell Death Differ. 13, 1776-1788 (2006).
52. Hoyt, D. G. et al. Integrin activation suppresses etoposide-induced DNA strand breakage in cultured murine tumor-derived endothelial cells. Cancer Res. 56, 4146-4149 (1996).
53. Nefedova, Y., Landowski, T. H. & Dalton, W. S. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 17, 1175-1182 (2003).
54. Borsellino, N. et al. Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer 85, 134-144 (1999).
55. Catlett-Falcone, R. et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10, 105-115 (1999).
56. Duan, Z. et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin. Cancer Res. 12, 5055-5063 (2006).
57. Frassanito, M. A., Cusmai, A., Iodice, G. & Dammacco, F. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 97, 483-489 (2001).
58. Perez, L. E. et al. Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP. J. Immunol. 180, 1545-1555 (2008).
59. Voorhees, P. M. et al. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin. Cancer Res. 13, 6469-6478 (2007).
60. Allinen, M. et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6, 17-32 (2004).
61. Arnulf, B. et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 21, 158-163 (2007).
62. Orimo, A. et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348 (2005).
63. Sanz-Rodriguez, F., Hidalgo, A. & Teixido, J. Chemokine stromal cell-derived factor-1α modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood 97, 346-351 (2001).
64. Kettritz, R., Choi, M., Rolle, S., Wellner, M. & Luft, F. C. Integrins and cytokines activate nuclear transcription factor-κB in human neutrophils. J. Biol. Chem. 279, 2657-2665 (2004).
65. Shain, K. H. et al. β1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res. 69, 1009-1015 (2009).
66. Tancred, T. M., Belch, A. R., Reiman, T., Pilarski, L. M. & Kirshner, J. Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance. J. Histochem. Cytochem. 57, 239-247 (2008).
67. White, D. E. et al. Addressing the role of cell adhesion in tumor cell dormancy. Cell Cycle 5, 1756-1759 (2006).
68. St. Croix, B. et al. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nature Med. 2, 1204-1210 (1996).
69. St. Croix, B. et al. Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. J. Natl Cancer Inst. 88, 1285-1296 (1996).
70. White, D. E. et al. Targeted disruption of β1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 6, 159-170 (2004).
71. Weaver, V. M. et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. 137, 231-245 (1997).
72. Goodison, S. et al. Prolonged dormancy and sitespecific growth potential of cancer cells spontaneously disseminated from nonmetastatic breast tumors as revealed by labeling with green fluorescent protein. Clin. Cancer Res. 9, 3808-3814 (2003).
73. Naumov, G. N. et al. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res. 62, 2162-2168 (2002).
74. Pantel, K. et al. Differential expression of proliferationassociated molecules in individual micrometastatic carcinoma cells. J. Natl Cancer Inst. 85, 1419-1424 (1993).
75. Gong, J., Ko, T. C. & Brattain, M. G. Disruption of fibronectin binding to the α5β1 integrin stimulates the expression of cyclin-dependent kinases and DNA synthesis through activation of extracellular signalregulated kinase. J. Biol. Chem. 273, 1662-1669 (1998).
76. Fischer, C. et al. Galectin-1 interacts with the α5β1 fibronectin receptor to restrict carcinoma cell growth via induction of p21 and p27. J. Biol. Chem. 280, 37266-37277 (2005).
77. Henriet, P., Zhong, Z. D., Brooks, P. C., Weinberg, K. I. & DeClerck, Y. A. Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. Proc. Natl Acad. Sci. USA 97, 10026-10031 (2000).
78. Nefedova, Y., Cheng, P., Alsina, M., Dalton, W. S. & Gabrilovich, D. I. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 103, 3503-3510 (2004).
79. Bisping, G. et al. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 101, 2775-2783 (2003).
80. Dankbar, B. et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95, 2630-2636 (2000).
81. Stupp, R. & Ruegg, C. Integrin inhibitors reaching the clinic. J. Clin. Oncol. 25, 1637-1638 (2007).
82. 2), a beta integrin antagonist, in patients with solid tumours. Br. J. Cancer 94, 1621-1626 (2006).
83. McNeel, D. G. et al. Phase I trial of a monoclonal antibody specific for αvβ3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin. Cancer Res. 11, 7851-7860 (2005).
84. v integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin. Cancer Res. 13, 2128-2135 (2007).
85. Reardon, D. A. et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol. 26, 5610-5617 (2008).
86. Sondergaard, T. E. et al. A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma. Hematol. Oncol. 27, 17-22 (2009).
87. Weitz-Schmidt, G. et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nature Med. 7, 687-692 (2001).
88. Weitz-Schmidt, G., Welzenbach, K., Dawson, J. & Kallen, J. Improved lymphocyte function-associated antigen-1 (LFA-1) inhibition by statin derivatives: molecular basis determined by x-ray analysis and monitoring of LFA-1 conformational changes in vitro and ex vivo. J. Biol. Chem. 279, 46764-46771 (2004).
89. Denoyelle, C. et al. Molecular mechanism of the anticancer activity of cerivastatin, an inhibitor of HMGCoA reductase, on agressive human breast cancer cells. Cell Signal 15, 327-338 (2003)
90. Schmidmaier, R. et al. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesionmediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood 104, 1825-1832 (2004).
91. Kinbara, K., Goldfinger, L. E., Hansen, M., Chou, F. L. & Ginsberg, M. H. Ras GTPases: integrins' friends or foes? Nature Rev. Mol. Cell Biol. 4, 767-776 (2003).
92. Azab, A. K. et al. Rho-A and Rac-1 GTPases play major and differential roles in SDF1-induced cell adhesion and chemotaxis in multiple myeloma. Blood 114, 619-629 (2009).
93. Schmidmaier, R. et al. First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma. Eur. J. Haematol. 79, 240-243 (2007).
94. Maeda, T., Kawane, T. & Horiuchi, N. Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation. Endocrinology 144, 681-692 (2003).
95. Mundy, G. et al. Stimulation of bone formation in vitro and in rodents by statins. Science 286, 1946-1949 (1999).
96. Landowski, T. H., Olashaw, N. E., Agrawal, D. & Dalton, W. S. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/ p50) in myeloma cells. Oncogene 22, 2417-2421 (2003).
97. San Miguel, J. F. et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359, 906-917 (2008).
98. Lin, B. et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 62, 5019-5026 (2002).
99. Bisping, G. et al. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma. Clin. Cancer Res. 15, 520-531 (2009).
100. Burger, M. et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 106, 1824-1830 (2005).
101. Zeng, Z. et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 113, 6215-6224 (2008).
102. Goldie, J. H. & Coldman, A. J. Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat. Rep. 67, 923-931 (1983).
103. Hazlehurst, L. A. et al. Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells. Cancer Res 66, 2338-2345 (2006).
104. Moshaver, B. et al. Chemotherapeutic treatment of bone marrow stromal cells strongly affects their protective effect on acute myeloid leukemia cell survival. Leuk. Lymphoma 49, 134-148 (2008).
105. Spiotto, M. T., Rowley, D. A. & Schreiber, H. Bystander elimination of antigen loss variants in established tumors. Nature Med. 10, 294-298 (2004).
106. Zhang, B. et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J. Exp. Med. 204, 49-55 (2007).
107. Zhang, B. et al. Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res. 68, 1563-1571 (2008).
108. Kirshner, J. et al. A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood 112, 2935-2945 (2008).